Title of article :
SARS-CoV-2 and probable lung cancer risk
Author/Authors :
Khiali ، Sajad Department of Clinical Pharmacy - Faculty of Pharmacy - Tabriz University of Medical Sciences , Rezagholizadeh ، Afra Department of Clinical Pharmacy - Faculty of Pharmacy - Tabriz University of Medical Sciences , Entezari-Maleki ، Taher Department of Clinical Pharmacy - Faculty of Pharmacy, Cardiovascular Research Center - Tabriz University of Medical Sciences
Abstract :
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global crisis with a growing number of mortalities and morbidities worldwide. Despite performing numerous researches, there are still considerable unrevealed details regarding the long-term complications and post-infection immunity of the coronavirus disease 2019 (COVID-19). Based on pathophysiological features, SARS-CoV-2 may act similarly as an oncovirus in the lung. This letter summarized three possible oncogenic mechanisms of SARS-CoV-2 that may be associated with lung cancer development.
Keywords :
COVID , 19 , SARS , CoV , 2 , Oncovirus , Lung cancer , Lung fibrosis
Journal title :
Bioimpacts
Journal title :
Bioimpacts